Home › Companies › NEUROGENE INC. › 2023-2024
At NEUROGENE INC.'s shareholder meeting held June 14, 2024, in the 2023-2024 proxy season, 56 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 153 separate fund positions. On the most widely held item on that ballot — To approve on an advisory (non-binding) basis the compensation of the Company's named executive… — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: NEUROGENE INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 17, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and NEUROGENE INC.’s Form 8-K, filed June 17, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 14, 2024: 4 items on NEUROGENE INC.’s Form 8-K, filed June 17, 2024: 4 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore NEUROGENE INC. in the interactive database Compare manager voting policies
These tallies are NEUROGENE INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 17, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Cory Freedland | 9,198,010 | -- | -- | 382,881 | 248,681 | 96% | Not verified | — |
| Elect Director: Rachel McMinn | 9,198,031 | -- | -- | 382,860 | 248,681 | 96% | Not verified | — |
| 2. Approval on an advisory (non-binding) basis of the compensation of the Company's named executive officers | 9,092,990 | 482,023 | 5,878 | -- | 248,681 | 95% | Not verified | — |
| 3. Ratification on an advisory (non-binding) basis of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024 | 9,826,384 | 1,361 | 1,827 | -- | -- | 99.9% | Not verified | — |
Source: NEUROGENE INC., Form 8-K, filed with the SEC on June 17, 2024 — read the filing on EDGAR.
Each item below shows how the 56 asset managers that disclosed a NEUROGENE INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors for terms expiring in 2027: Cory Freedland
NEUROGENE INC.’s own tally for this item (“Elect Director: Cory Freedland”): 9,198,010 for, 382,881 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 643,343 | 0 | 0 | 0 | For |
| Vanguard | 460,549 | 0 | 0 | 0 | For |
| Fidelity | 89,959 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 59,062 | 0 | 0 | 0 | For |
| Charles Schwab | 5,239 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 2,515 | Withhold |
| Invesco | 2,042 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 734 | Withhold |
| Brighthouse | 0 | 0 | 0 | 450 | Withhold |
| John Hancock | 0 | 0 | 408 | 0 | Abstain |
| MERIDIAN FUND INC | 254 | 0 | 0 | 0 | For |
| Guggenheim | 0 | 0 | 0 | 10 | Withhold |
| Nationwide | 0 | 0 | 0 | 8 | Withhold |
Fund voting reports, all 13 managers: 1,260,448 for, 3,717 withheld, 408 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Altium Capital Management LP | 100,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 100,000 for.
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors for terms expiring in 2027: Rachel McMinn
NEUROGENE INC.’s own tally for this item (“Elect Director: Rachel McMinn”): 9,198,031 for, 382,860 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 643,343 | 0 | 0 | 0 | For |
| Vanguard | 460,549 | 0 | 0 | 0 | For |
| Fidelity | 89,959 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 59,062 | 0 | 0 | 0 | For |
| Charles Schwab | 5,239 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 2,515 | Withhold |
| Invesco | 2,042 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 734 | Withhold |
| Brighthouse | 0 | 0 | 0 | 450 | Withhold |
| John Hancock | 0 | 0 | 408 | 0 | Abstain |
| MERIDIAN FUND INC | 254 | 0 | 0 | 0 | For |
| Guggenheim | 0 | 0 | 0 | 10 | Withhold |
| Nationwide | 0 | 0 | 0 | 8 | Withhold |
Fund voting reports, all 13 managers: 1,260,448 for, 3,717 withheld, 408 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Altium Capital Management LP | 100,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 100,000 for.
Combines 8 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To approve on an advisory (non-binding) basis the compensation of the Company's named executive officers.
NEUROGENE INC.’s own tally for this item (“2. Approval on an advisory (non-binding) basis of the compensation of the Company's named executive officers”): 9,092,990 for, 482,023 against, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 643,343 | 0 | 0 | 0 | For |
| Vanguard | 460,549 | 0 | 0 | 0 | For |
| Fidelity | 0 | 89,959 | 0 | 0 | Against |
| JANUS INVESTMENT FUND | 59,062 | 0 | 0 | 0 | For |
| Charles Schwab | 5,239 | 0 | 0 | 0 | For |
| American Century | 0 | 2,515 | 0 | 0 | Against |
| Invesco | 2,042 | 0 | 0 | 0 | For |
| Dimensional | 0 | 734 | 0 | 0 | Against |
| Brighthouse | 0 | 0 | 450 | 0 | Abstain |
| John Hancock | 0 | 408 | 0 | 0 | Against |
| MERIDIAN FUND INC | 254 | 0 | 0 | 0 | For |
| Guggenheim | 0 | 10 | 0 | 0 | Against |
| Nationwide | 0 | 8 | 0 | 0 | Against |
Fund voting reports, all 13 managers: 1,170,489 for, 93,634 against, 450 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 1,860,990 | 0 | 0 | 0 | For |
| Samsara BioCapital, LLC | 1,267,790 | 0 | 0 | 0 | For |
| GREAT POINT PARTNERS LLC | 1,001,906 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 915,760 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 833,716 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 348,275 | 0 | 0 | 0 | For |
| COMMODORE CAPITAL LP | 200,000 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 | 161,900 | 0 | 0 | Against |
| Cormorant Asset Management, LP | 157,334 | 0 | 0 | 0 | For |
| Janus Henderson | 135,319 | 8 | 0 | 0 | For |
| Altium Capital Management LP | 100,000 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 98,314 | 0 | 0 | Against |
| Nantahala Capital Management, LLC | 66,018 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 53,619 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 0 | 45,654 | 0 | 0 | Against |
| Goldman Sachs | 42,457 | 0 | 0 | 0 | For |
| Point72 | 0 | 38,808 | 0 | 0 | Against |
| Avidity Partners Management LP | 37,791 | 0 | 0 | 0 | For |
| Renaissance | 0 | 35,869 | 0 | 0 | Against |
| Northern Trust | 11,153 | 0 | 0 | 0 | For |
| BlackRock | 10,998 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 0 | 9,899 | 0 | 0 | Against |
| EAM Investors, LLC | 0 | 6,430 | 0 | 0 | Against |
| Charles Schwab | 5,239 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 5,180 | 0 | 0 | 0 | For |
Institutional-manager reports, all 49 managers: 7,068,309 for, 408,575 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: To ratify on an advisory (non-binding) basis of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting rm for the year ending December 31, 2024.
NEUROGENE INC.’s own tally for this item (“3. Ratification on an advisory (non-binding) basis of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024”): 9,826,384 for, 1,361 against, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 643,343 | 0 | 0 | 0 | For |
| Vanguard | 460,549 | 0 | 0 | 0 | For |
| Fidelity | 89,959 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 59,062 | 0 | 0 | 0 | For |
| Charles Schwab | 5,239 | 0 | 0 | 0 | For |
| American Century | 2,515 | 0 | 0 | 0 | For |
| Invesco | 2,042 | 0 | 0 | 0 | For |
| Dimensional | 734 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 450 | 0 | Abstain |
| John Hancock | 408 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 254 | 0 | 0 | 0 | For |
| Guggenheim | 10 | 0 | 0 | 0 | For |
| Nationwide | 8 | 0 | 0 | 0 | For |
Fund voting reports, all 13 managers: 1,264,123 for, 450 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Altium Capital Management LP | 100,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 100,000 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 12,980,289 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 4.96% |
| 2 | Vanguard | 3.55% |
| 3 | Fidelity | 0.69% |
| 4 | JANUS INVESTMENT FUND | 0.46% |
| 5 | Charles Schwab | 0.04% |
| 6 | American Century | 0.02% |
| 7 | Invesco | 0.02% |
| 8 | Dimensional | <0.01% |
| 9 | Brighthouse | <0.01% |
| 10 | John Hancock | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | EcoR1 Capital, LLC | 14.34% |
| 2 | Samsara BioCapital, LLC | 9.77% |
| 3 | GREAT POINT PARTNERS LLC | 7.72% |
| 4 | Redmile Group, LLC | 7.06% |
| 5 | RTW INVESTMENTS, LP | 6.42% |
| 6 | ArrowMark Colorado Holdings LLC | 2.68% |
| 7 | COMMODORE CAPITAL LP | 1.54% |
| 8 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.25% |
| 9 | Cormorant Asset Management, LP | 1.21% |
| 10 | Janus Henderson | 1.04% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Samsara BioCapital, L.P. | — | 13G |
| RTW Investments, LP | — | 13G |
| Baker Bros. Advisors LP | — | 13G |
| Redmile Group, LLC | — | 13G |
| Casdin Capital, LLC | — | 13G |
| Entities affiliated with EcoR1 Capital Fund, L.P. | — | DEF14A |
| Rachel McMinn | — | DEF14A |
| Entities affiliated with Redmile Biopharma Investments I, L.P. | — | DEF14A |
| Entities affiliated with Great Point Partners, LLC | — | DEF14A |
| BlackRock | — | 13F |
Percentages above are of 12,980,289 shares outstanding, as reported by NEUROGENE INC. on its Form 10-Q dated May 6, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NEUROGENE INC.’s 10-Q dated May 6, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
NEUROGENE INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
proxyvotesnow.com, “NEUROGENE (NGNE) 2024 Annual Meeting: Vote Results & How Funds Voted”, https://proxyvotesnow.com/company/neurogene-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.